Boundless Bio Presents Preclinical Data on the Discovery of its Second ecDNA-Directed Therapeutic Candidate, BBI-825, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Preclinical findings support the advancement of BBI-825, a novel, orally available, selective inhibitor of ribonucleotide reductase (RNR), as a differentiated t... Read more.
Franklin Templeton Closed-End Funds Announce Share Repurchases for the Third Quarter of 2023
NEW YORK–(BUSINESS WIRE)–The following Funds announced today their share repurchase activity during the third quarter of 2023. Ticker Fund Name Shar... Read more.
Marti Reports 2023 First Half Results; Investing in Scaling Ride-Hailing
ISTANBUL–(BUSINESS WIRE)–Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye’s mobility super app, today an... Read more.
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
WILMINGTON, Del.–(BUSINESS WIRE)–$INCY–Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring new data from the company’s cl... Read more.
Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023
— STX-241 is designed to be a highly selective, CNS-penetrant, fourth generation EGFR inhibitor with a potential best-in-class profile that addresses resi... Read more.
Power Integrations to Release Third-Quarter Financial Results on November 7
SAN JOSE, Calif.–(BUSINESS WIRE)–Power Integrations (Nasdaq: POWI) will release its third-quarter financial results after market hours on Tuesday, N... Read more.
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
Opinion granted based on positive overall survival results from the Phase 3 KEYNOTE-859 trial If approved, a KEYTRUDA combination would become an option in the ... Read more.
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
– PHOENIX Phase 3 trial topline results on track for mid-2024 and will inform regulatory next steps in the EU – Final decision from the European Com... Read more.
Legends Real Estate Joins The Real Brokerage
56-agent brokerage grows Real’s presence in Northern California TORONTO & NEW YORK–(BUSINESS WIRE)–$REAX #therealbrokerage–The Real Brok... Read more.
Global Oil and Gas EPC (Engineering, Procurement, and Construction) Industry Report 2023: Market Trends, Share, Size, Growth, Opportunities and Forecasts, 2022 & 2023-2028 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Oil and Gas EPC Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” rep... Read more.